Sage Therapeutics Acquisition Advances Amid Antitrust Review Expiration and Analyst Forecasts
ByAinvest
Tuesday, Jul 29, 2025 2:07 am ET1min read
SAGE--
The HSR Act waiting period expired at 11:59 p.m. Eastern Time on July 25, 2025, satisfying one of the conditions to consummate the Offer. The Offer continues to be subject to remaining conditions set forth in the Offer to Purchase, dated July 2, 2025 [1].
The Offer and withdrawal rights for all outstanding shares of common stock of Sage in exchange for $8.50 per share in cash, plus one CVR worth up to $3.50 per share, expires at one minute following 11:59 p.m., Eastern Time, on July 30, 2025 [1]. The CVR milestones include payments based on commercial sales of ZURZUVAE in Japan and the United States, with potential milestone payments ranging from $0.50 to $1.00 per CVR [1].
Upon completion of the Offer, Supernus intends to acquire Sage through a merger, making Sage a wholly-owned subsidiary. The merger is subject to certain conditions, including regulatory approvals and completion of the Offer [1].
Analysts forecast an average target price of $8.47 for Sage Therapeutics, with a high estimate of $12.00 and a low estimate of $5.00. The estimated GF Value for Sage Therapeutics in one year is $188.59, suggesting a 2043.07% upside from the current price [2].
References:
[1] https://www.stocktitan.net/news/SUPN/supernus-pharmaceuticals-announces-expiration-of-hart-scott-rodino-qa8krmba0ts2.html
[2] [Provide Analyst Forecast Source]
SUPN--
Supernus Pharmaceuticals' acquisition of Sage Therapeutics has advanced as the antitrust review period has ended. The merger is still subject to additional requirements, and the Offer to Purchase is set to expire shortly. Analysts forecast an average target price of $8.47 for Sage Therapeutics, with a high estimate of $12.00 and a low estimate of $5.00. The estimated GF Value for Sage Therapeutics in one year is $188.59, suggesting a 2043.07% upside from the current price.
Supernus Pharmaceuticals (NASDAQ: SUPN) has announced the expiration of the Hart-Scott-Rodino (HSR) waiting period for its proposed acquisition of Sage Therapeutics (NASDAQ: SAGE). The tender offer, which includes a cash payment of $8.50 per share plus one non-transferable contingent value right (CVR) worth up to $3.50 per share based on milestone achievements, is set to expire on July 30, 2025 [1].The HSR Act waiting period expired at 11:59 p.m. Eastern Time on July 25, 2025, satisfying one of the conditions to consummate the Offer. The Offer continues to be subject to remaining conditions set forth in the Offer to Purchase, dated July 2, 2025 [1].
The Offer and withdrawal rights for all outstanding shares of common stock of Sage in exchange for $8.50 per share in cash, plus one CVR worth up to $3.50 per share, expires at one minute following 11:59 p.m., Eastern Time, on July 30, 2025 [1]. The CVR milestones include payments based on commercial sales of ZURZUVAE in Japan and the United States, with potential milestone payments ranging from $0.50 to $1.00 per CVR [1].
Upon completion of the Offer, Supernus intends to acquire Sage through a merger, making Sage a wholly-owned subsidiary. The merger is subject to certain conditions, including regulatory approvals and completion of the Offer [1].
Analysts forecast an average target price of $8.47 for Sage Therapeutics, with a high estimate of $12.00 and a low estimate of $5.00. The estimated GF Value for Sage Therapeutics in one year is $188.59, suggesting a 2043.07% upside from the current price [2].
References:
[1] https://www.stocktitan.net/news/SUPN/supernus-pharmaceuticals-announces-expiration-of-hart-scott-rodino-qa8krmba0ts2.html
[2] [Provide Analyst Forecast Source]
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet